Mark Lindsey, DO
Family Medicine · Montgomery, ALNPI 1225124829
Payments from drug & device makers
Across 365 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$917
- AbbVie$637
- Amgen$616
- GSK$483
- IBSA Pharma Inc.$371
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$240%
- Food & beverage$6,75299%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 62 | $1,040 |
| AstraZeneca | 38 | $917 |
| AbbVie(2 entities) | 43 | $637 |
| Amgen | 34 | $616 |
| GSK | 24 | $483 |
| IBSA Pharma Inc. | 19 | $371 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $355 |
| Kowa Pharmaceuticals America, Inc. | 17 | $355 |
| Lilly USA, LLC | 21 | $322 |
| Pfizer | 13 | $231 |
| Amarin Pharma, Inc. | 8 | $157 |
| Bayer | 6 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $110 |
| Inspire Medical Systems, Inc. | 2 | $107 |
| Phathom Pharmaceuticals, Inc. | 2 | $104 |
| Merck | 6 | $81 |
| Johnson & Johnson | 5 | $81 |
| Adlon Therapeutics L.p. | 4 | $66 |
| Esperion Therapeutics, Inc. | 3 | $64 |
| Astellas Pharma US Inc | 3 | $61 |
| Boehringer Ingelheim | 4 | $60 |
| Novartis | 3 | $53 |
| Aytu Biopharma, Inc. | 3 | $49 |
| Tris Pharma Inc | 3 | $48 |
| Radius Health, Inc. | 2 | $38 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Galderma Laboratories, L.p. | 1 | $30 |
| Eisai Inc. | 2 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Abbott | 1 | $23 |
| Bioventus LLC | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,793 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $49,679 |
| JardianceEmpagliflozin | 42 | $38,028 |
| EliquisApixaban | 51 | $37,836 |
| MounjaroTirzepatide | 24 | $32,592 |
| JanuviaSitagliptin Phosphate | 28 | $27,315 |
| XareltoRivaroxaban | 13 | $11,636 |
| Repatha SureclickEvolocumab | 13 | $11,281 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,031 |
| Testosterone | 31 | $7,359 |
| EdarbiAzilsartan Medoxomil | 18 | $7,026 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,725 |
| Pregabalin | 19 | $5,318 |
| Atorvastatin Calcium | 295 | $5,010 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $4,560 |
| Ezetimibe | 100 | $4,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,040 | $49,67950 claims |
| Boehringer IngelheimJardiance | $60 | $38,02842 claims |
| PfizerEliquis | $231 | $37,83651 claims |
| Lilly USA, LLCMounjaro | $322 | $32,59224 claims |
| MerckJanuvia, Janumet Xr | $81 | $31,87439 claims |
| Johnson & JohnsonXarelto | $81 | $11,63613 claims |
| GSKTrelegy Ellipta | $483 | $10,03114 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $35 | $7,02618 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $110 | $5,72512 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $4,075201 claims |
| AbbVieSynthroid | $637 | $3,02927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Montgomery
- Thavatchai ChamnongchareonwongMontgomery$18K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.